Clinical Trial

Chongqing Primary Aldosteronism Study

Recruiting
View on ClinicalTrials.gov →
Summary
We intends to conduct a series of original clinical research about PA, and establish a large cohort of PA and essential hypertension patients with long-term follow-up of cardiovascular events, renal end points etc. We will establish a large sample of blood, urine, adrenal tissue of the subjects, and the genomics,metabonomics, proteomics database, to explore the mechanism of the PA and target organ damage, risk factors, diagnostic methods and biomarkers.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2017-07-18; most recent amendment 2023-09-04.
Status change: Active, Not Recruiting → Recruiting 2021-08-22
Status change: Recruiting → Active, Not Recruiting 2019-01-29
Trial Details
NCT Number NCT03224312
Lead Sponsor Chongqing Medical University
Conditions Primary Aldosteronism
Enrollment 1,500 participants
Start Date 2016-10-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-09-06